Taigen Biotechnology Company, Ltd.

National Health Research Institutes

Teco Image Systems Co., Ltd.

Ming-Chu Hsu

Chu-Chung Lin

Shu-Jen Chen

Wen-Tai Li

Chiung-Tong Chen

Der-Ren Hwang

Chi-Feng Yen

Chi-Hsin Richard King

Wen-Chang Chen

Yibin Xiang

Kak-Shan Shia

Shin-Ru Shih

Jyh-Haur Chern

Shan-Yen Chou

Ying-Huey Huang

Chun-Wei Kuo

Chung-Ming Chang

Ching-Cheng Wang

Syaulan Yang

Jen-Dar Wu

Feng-Yih Su

Han-Pei Hsu

Shao-Ying Liao

Nai-Wun Luo

Hung-Chuan Chen

Chiayn Chiang

Luke Lin

Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: Ais CRor N; Ais CRRor NR; Ais CR'R&#x2032; or NR&#x2032;; each of R, R, R&#x2032;, R, R&#x2032;, R, R, R&#x2032;, R, R&#x2032;, R, and R&#x2032;, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, Calkyl, Calkenyl, Calkynyl, Calkoxy, Calkenyloxy, Calkylcarbonyl, Calkyloxycarbonyl, Calkylamine, Ccarbocyclyl, or Cheterocyclyl; or Rand R, R&#x2032; and R&#x2032;, or Rand R&#x2032;, together with the adjacent atom to which they are each attached, form Ccarbocyclyl or Cheterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.

Cap-dependent endonuclease inhibitors

A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: in which Ris C-Calkyl or C-Ccycloalkyl and the trans-isomeric compound has a trans:cis ratio of at least 70:30. Further disclosed is a method for preparing the trans-isomeric compound.

Trans-isomeric heterocyclic compounds and preparation thereof

A spray-dried solid dispersion containing a pharmaceutical compound of formula (I) shown below and a pharmaceutically acceptable polymer, 

Solid dispersion formulation

A scanner capable of executing a static calibration and a compensation value adjustment method therefor are disclosed. The scanner includes a calibration piece, a memory, an image capturing unit and a processing unit. The image capturing unit acquires an initial scanned pixel data. A compensation offset-ratio data having a first offset-ratio average is generated according to the initial scanned pixel data and a standard compensation data by the processing unit. Plural selected pixels are determined according to the compensation offset-ratio data, the first offset-ratio average and the predetermined compensation threshold value. A second offset-ratio average is obtained by removing the compensation offset-ratio values of the compensation offset-ratio data of the selected pixels. The initial scanned pixel data is transformed into a static compensation pixel data according to the second offset-ratio average and the standard compensation data.

Scanner capable of executing static calibration and compensation value adjustment method therefor

A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification): The method can be used to treat cancer and myocardial infarction.

Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor

This invention relates to a method of treating infection by methicillin-nonsusceptibale bacteria, vancomycin-nonsusceptibale bacteria, penicillin-nonsusceptibale bacteria, clarithromycin-nonsusceptibale bacteria, or metronidazole-nonsusceptibale bacteria by administering to a subject in need thereof an effective amount of a compound of the following formula: 

Treatment of antibiotic-resistant bacteria infection

This invention relates to treating cancer or an angiogenesis-related disease using a compound of formula 1: wherein R, R, R, R, and n are defined herein.

Methods of 1H-indol-3-yl-2-oxoacetamide compounds

This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (II). Each variable is defined in the specification. 

Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases

A method of treating cancer including administering to a subject in need thereof an effective amount of a compound of the formula 1: wherein R, R, R, R, and n are as defined herein.

Use of 1H-indol-3-yl-2-oxoacetamide compounds

The invention is based on the discovery that certain 3-oxoacetamideindolyl compounds have potent anticancer and anti-angiogenic activity. The 3-oxoacetamideindolyl compounds are of the following formula.In this formula, each Ris independently isoxazolyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, isoquinolyl, thionaphthenyl, or benzofuranyl, each being optionally substituted with 1-6 independent R; or when taken together with Rand the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R. Each Ris independently H, C1-C10 alkyl, or aryl, each being optionally substituted with 1-4 independent R; or when taken together with Rand the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R. Each Ris independently C3-C10 cycloalkyl, C4-C10 cycloalkenyl, isoxazolyl, furanyl, thiophenyl, thiazolyl, imidazolyl, pyridyl, or heterocyclyl, each being optionally substituted with 1-4 independent R. Each Ris independently H, NO, halo, CN, R, OR, COR, SR, NRR, C(O)R, C(O)NRR, OC(O)R, S(O)R, S(O)NRR, NRC(O)NRR, NRC(O)R, NR(COOR), NRS(O)NRR, NRS(O)R, or S(O)OR.

Indol-3-YL-2-oxoacetamide compounds and methods of use thereof

Imidazolidinone compounds

Growing community of inventors

Glendora, CA, United States of America

Ming-Chu Hsu